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Abstract
Regulation of intracellular deoxynucleoside triphosphate (dNTP) pool is critical to genomic stability and cancer
development. Imbalanced dNTP pools can lead to enhanced mutagenesis and cell proliferation resulting in cancer
development. Therapeutic agents that target dNTP synthesis and metabolism are commonly used in treatment of
several types of cancer. Despite several studies, the molecular mechanisms that regulate the intracellular dNTP
levels and maintain their homeostasis are not completely understood. The discovery of SAMHD1 as the first
mammalian dNTP triphosphohydrolase provided new insight into the mechanisms of dNTP regulation. SAMHD1
maintains the homeostatic dNTP levels that regulate DNA replication and damage repair. Recent progress indicates
that gene mutations and epigenetic mechanisms lead to downregulation of SAMHD1 activity or expression in
multiple cancers. Impaired SAMHD1 function can cause increased dNTP pool resulting in genomic instability and
cell-cycle progression, thereby facilitating cancer cell proliferation. This review summarizes the latest advances in
understanding the importance of dNTP metabolism in cancer development and the novel function of SAMHD1 in
regulating this process.
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Introduction
Balanced levels of intracellular dNTPs, the building
blocks of DNA, are critical in maintaining the genomic
integrity of cells. While a reduction or imbalance in
dNTPs is known to result in genotoxicity and increased
mutagenesis, an increase in dNTPs often results in un-
controlled DNA replication with reduced fidelity that
can contribute to cancer development [1, 2]. Indeed during
DNA replication, an unequal and abnormal increase in
concentrations of specific dNTPs may result in reduced fi-
delity [1, 2]. Many types of cancer cells demonstrate impair-
ment of intracellular dNTP homeostasis, which supports
rapid cellular proliferation, enhanced mutagenesis, and con-
tributes to dysregulation of the cell cycle [3]. Nucleotide
metabolism, therefore, is a common therapeutic target used
in the treatment of many types of cancer. Nucleoside ana-
logs as well as enzyme inhibitors aim to disrupt the syn-
thetic pathways which result in imbalance of dNTPs in
cancer cells [4]. However, the integrated mechanisms, such
as anabolic and catabolic pathways, cell cycle control, and
DNA repair, which result in impaired dNTP homeostasis in
cancer, are incompletely understood.
The intracellular dNTP balance is regulated in part by
sterile alpha motif (SAM) and histidine/aspartate (HD)-
domain containing protein 1 (SAMHD1), the first dNTP
triphosphohydrolase (dNTPase) discovered in mamma-
lian cells [5–8]. SAMHD1 acts as the host restriction
factor that inhibits human immunodeficiency virus type
1 (HIV-1) infection by reducing intracellular dNTP levels
[9]. Human SAMHD1 mutations can cause a severe auto-
immune disorder [10], suggesting the importance of its
dNTPase function in innate immunity. Mutations of
SAMHD1 have been identified in several human cancers
[11–19]. SAMHD1 expression is downregulated in many
cancers, including leukemia, lymphoma, and solid cancers,
such as breast and lung cancer [11, 20, 21]. Restoration of
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SAMHD1 expression has been reported to reduce cel-
lular proliferation in vitro [11, 21]. Based on these re-
cent findings, SAMHD1 is proposed to have anti-
proliferative and tumor suppressive functions in several
cancers. Since dNTP metabolism and balance is critical
in carcinogenesis, the dNTPase activity of SAMHD1
may mediate its tumor suppressive function. Despite
several advancements in in the use of therapeutic nu-
cleoside analogs to target dNTP metabolism, there is
yet a need to develop novel and more effective thera-
peutic strategies in cancer treatment. Further studies to
understand the physiological significance of SAMHD1
in cancer can aid in this process.
Although numerous studies have investigated the
dNTPase function of SAMHD1 in viral restriction and im-
mune responses, its significance in cancer development
and progression has lately been an emerging interest.
Functional significance of SAMHD1 and its dNTPase ac-
tivity in cancer pathophysiology has not yet been reviewed.
Here we highlight the importance of dNTP homeostasis in
cancer and dNTP regulation by SAMHD1. We also discuss
the potential role of SAMHD1 as a tumor suppressor and
future studies required to better understand its function
for cancer therapeutic development.
Regulation of intracellular dNTPs and its role in
cancer
Intracellular dNTP synthesis and regulation
Coordinated synthesis and degradation of dNTPs
resulting in a balanced intracellular dNTP pool is crit-
ical for numerous cellular processes, such as fidelity of
DNA synthesis and DNA damage repair [22]. Two dis-
tinct pathways that synthesize dNTPs are the de novo
synthesis in the cytoplasm, and the salvage pathway
that takes place both in cytoplasm and mitochondria.
The rate-limiting step of de novo dNTP synthesis is cat-
alyzed by ribonucleotide reductase (RNR) that converts
ribonucleotide diphosphates to deoxyribonucleotides
[3]. Degradation of dNTPs as part of the salvage path-
way is accomplished by deaminases and phosphory-
lases, as well as the mammalian triphosphohydrolase,
SAMHD1 [7, 8]. Optimization of dNTP pools is
achieved by cell cycle-dependent activity and allosteric
regulation of RNR and SAMHD1 [23]. Actively prolif-
erating cells have an approximately 10-fold higher
dNTP pool than quiescent cells that are in G0/G1 phase
[24]. The dNTP pool is greatly expanded during G1 to
S-phase transition, and remains abundant until DNA
synthesis is complete [24]. This biphasic regulation is
critical to supply dNTPs for DNA synthesis, and to
prevent excess intracellular dNTPs in the absence of
DNA replication, which can contribute to innate im-
mune activation [25] and cancer development [22].
Dysregulation of dNTP in cancer development
The complement of intracellular dNTPs has numerous
implications for DNA replication, mutagenesis, DNA re-
pair, and therefore in cancer development. Recent pro-
gress in literature suggests that RNR-mediated increase
in dNTP pools is accompanied by higher mutation rates
due to reduced fidelity of DNA replication or activation
of translesion synthesis [26]. These studies suggest that
increased dNTP pools upon altered RNR activity may
cause increased mutation rates. However, it is important
to note that altered RNR activity can also affect its func-
tion in DNA repair (25). Therefore, further studies are
required to rule out the possibility of altered DNA repair
functions of RNR leading to increased mutation rate. In-
deed, dNTP pools are generally greater in transformed
cell lines compared to normal cells [27]. Mutator pheno-
types are characterized by increased somatic mutation
frequency in pre-cancerous cells that accounts for high
number of mutations in cancer cells, consistent with what
is observed with dNTP pool imbalances [24, 28, 29].
These pre-cancerous cells are characterized by enhanced
mutagenesis, stimulation of genetic recombination, in-
creased frequency of chromosomal abnormalities, DNA
strand breaks and cell death [26]. Imbalance in cellular
dNTP pool causes a hypermutator phenotype, associated
with DNA replication stress and altered replication fork
velocity [3, 11]. Mechanisms of mutagenesis conferred by
imbalanced dNTP pool are not fully understood, but likely
include nucleotide misinsertion during DNA replication,
indirect inhibition of proof-reading, or forced frameshift
mutations [26].
In response to DNA damage, dNTP levels in S-phase
increase approximately by 4-fold [30]. Both RNR and
SAMHD1 can be recruited to sites of DNA damage to
tightly regulate the dNTPs supplied for DNA repair ma-
chinery [11, 30]. Replication stress from increased muta-
tion rate contributes to genomic instability and activates
the DNA damage response, which then may further ex-
acerbate mutagenesis by altering the balance of the
dNTP pool [31, 32]. It is interesting to note that pre-
cancerous cells show evidence of increased DNA dam-
age response activation [31, 32]. Together, these studies
suggest that in cells with elevated activation of DNA
damage responses, increased dNTP levels may lead to
malignancy.
Nucleotide metabolism plays an important role in sen-
escence and autophagy in cancer cells. Senescence may
occur as a tumor suppressive mechanism early on in
tumor initiation, while autophagy is a common mechan-
ism that tumor cells use to survive under metabolic
stress [3, 33]. Nucleotide metabolism therefore has im-
plications in genomic instability and mutation as part of
tumor initiation, and resistance to apoptosis during
tumor promotion, two of the important hallmarks of
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cancer development. Thus, regulators of dNTP pool are
important targets of cancer therapy.
Current cancer therapy targeting dNTP metabolism
Given the important role of nucleotide metabolism in
cell proliferation, transformation and tumor progression,
inhibition of nucleotide synthesis has been commonly
used in treatment of cancer, as well as infectious and
immune-mediated diseases [3]. Inhibiting DNA precur-
sor synthesis or incorporation of nucleoside analogs into
DNA results in DNA damage and stalled replication
forks, followed by activation of the S-phase checkpoint,
which may lead to cell death by apoptosis [3] (Fig. 1).
Methotrexate and similar compounds that inhibit dihy-
drofolate reductase required for purine biosynthesis
[34], are widely used in chemotherapy for solid and
lymphocytic tumors. On the other hand, purine and
pyrimidine analogs such as forodesine and gemcitabine
respectively, can disrupt DNA replication [35]. More-
over, 5-fluorouracil is a pyrimidine adduct that is misin-
corporated into DNA and inhibits nucleotide synthesis
[34]. Most of clinically available nucleoside analogs act by
incorporation into DNA, which relies on balanced dNTP
pool for high fidelity of incorporation during replication.
Excess intracellular dNTPs may out-compete these nu-
cleoside analogs, thus conferring chemotherapeutic resist-
ance [36]. For this reason, these drugs may be used in
combination with other therapies, such as inhibitors of
RNR that reduce dNTP pool. Efficient RNR inhibition is
accomplished by hydroxyurea, a free radical scavenger and
iron chelator that inactivates the catalytic capacity of the
R2 subunit of RNR [3]. Current clinically used inhibitors
of RNR, such as hydroxyurea or gemcitabine, have limita-
tions, including severe cytotoxicity, short half-life, and
drug resistance when used as a single therapy. New hori-
zons for nucleotide synthesis-directed therapy include
Fig. 1 Dysregulation of dNTPs in cancer pathogenesis and its targeted therapy. Nucleotides are derived from multiple intracellular sources,
including products of glycolysis, folate cycle, and scavenging of degraded components. The reduction of dihydrofolate to active tetrahydrofolate
is inhibited by the chemotherapeutic methotrexate. Pyrimidine and purine bases are both reduced to deoxynucleosides (dN) by ribonucleotide
reductase (RNR). This reaction is inhibited by the chemotherapeutic hydroxyurea. Other steps in this reaction are inhibited by numerous nucleoside
analogs (“antimetabolite” compounds) including 5-fluorouracil. These drugs function by limiting the deoxynucleoside triphosphate (dNTP)
pool available for DNA synthesis and triggering the S-phase checkpoint via the action of ATR and Chk1, resulting in cell cycle arrest by
inhibiting the activation of cyclin dependent kinase 1 (CDK1). A potentially critical regulator of this pathway is SAMHD1, which hydrolyses
dNTPs into products that are then recycled or degraded. By this action, SAMHD1 limits dNTP pool in G1 phase and prevents DNA replication. With loss of
function or repression of SAMHD1 expression, the dNTP pool is not reduced which can result in DNA damage and inappropriate cell cycle progression.
DHFR, dihydrofolate reductase; PPPs, triphosphate; ATR, ataxia-telangiectasia and Rad3-related protein; Cdc25, cell division cycle 25
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small molecule targeting subunit activity modulation, such
as anti-sense oligonucleotides and gene therapy targeting
RNR [3, 26].
It is currently unclear whether SAMHD1 can degrade
these nucleoside analogs in cells and reduce their anti-
cancer potency. A study indicates that reduction of
SAMHD1 levels in T-cells significantly decreases HIV-1
sensitivity to thymidine analogs (such as zidovudine or
stavudine), but not other tested nucleotide analogs of
HIV-1 reverse transcriptase inhibitors [37]. These results
suggest that SAMHD1 may have a differential effect over
the different dNTPs. Owing to its dNTPase activity,
SAMHD1 may serve as an intriguing target of cancer
therapy as reduction of dNTP pool may prevent tumori-
genesis or an increase in efficacy of anti-nucleotide che-
motherapeutics (Fig. 1).
Regulation of nucleotide metabolism by dNTP
hydrolysis
Regulating dNTP homeostasis
SAMHD1 was identified in human myeloid cells as a
novel HIV-1 restriction factor [5, 6]. SAMHD1 is respon-
sible for maintaining low levels of intracellular dNTPs in
non-dividing cells [9, 38, 39]. In non-transformed fibro-
blasts, knockdown of SAMHD1 results in loss of cell-
cycle regulation, and cells accumulate in G1 with oversized
dNTP pool [40]. Therefore, SAMHD1 influences cell cycle
progression and DNA replication by degrading dNTPs
[40] (Fig. 1). SAMHD1 siRNA-mediated knockdown has
differential effects on the dNTP pools of proliferating cells
and quiescent cells [40]. In proliferating lung or skin fibro-
blasts, siRNA-mediated knockdown of SAMHD1 leads to
loss of the cell-cycle regulation of dNTP pool sizes and
thus resulting in dNTP imbalance [40]. On the other
hand, in cells made quiescent via serum starvation,
SAMHD1 down-regulation leads to a marked expansion
of dNTP pools [40]. The function of SAMHD1 in sensing
intracellular dNTPs is critical for maintaining pool bal-
ance in cells at the appropriate phase in cell cycle.
The opposite role of increasing the intracellular dNTP
pool is achieved by RNR, which catalyzes the rate-limiting
step in de novo nucleotide synthesis by converting ribonu-
cleotides to deoxyribonucleotides [3, 24]. RNR heterote-
tramer is present at consistent levels throughout the cell
cycle and functions in de novo nucleotide synthesis even
in non-dividing cells [27]. The gene encoding the active
subunit, R1, is transcriptionally regulated, responding to
DNA replication stress and progression through the cell
cycle [31]. RNR transcription increases by 10–20 fold in S
phase over the levels in G1 phase [27, 31]. RNR can also
be recruited to sites of DNA damage, by the virtue of p53-
inducible subunit R2, to supply the necessary dNTPs for
the damage repair machinery [27]. Cancer cells require
RNR for de novo synthesis of dNTPs and elevated RNR
expression is a characteristic of many cancers, which con-
tribute to increased dNTP levels and uncontrolled cellular
proliferation [27].
Both SAMHD1 and RNR have similar regulation
mechanisms of their expression and activity, which are
cell-cycle dependent and tightly controlled in cells. Both
enzymes are active oligomers with two types of allosteric
sites that sense the concentration of nucleotides in the
cell and control enzymatic activity [23, 24, 41]. Regula-
tion of SAMHD1 dNTPase activity is achieved by allo-
steric binding of dGTP or GTP to the first allosteric site,
followed by binding of any dNTP to the second allo-
steric site, causing a conformational change in the
substrate-binding pocket [23, 42]. SAMHD1 has sensory
activity that detects the cellular dNTP pool composition,
and allows a feedback system to achieve a balance with
the opposite catalytic activity of RNR [23, 41]. The most
sensitive regulator of dNTP pool is likely dATP, as it has
higher affinity for the second allosteric site of SAMHD1,
weak affinity for the catalytic site of SAMHD1, and is pro-
duced least efficiently by RNR [26, 43]. The dATP:ATP ra-
tio is likewise an important regulator of RNR activity [26].
Elevations in dATP concentrations are inhibitory to the
anabolic activity of RNR, whereas increased ATP concen-
tration is stimulatory [26]. Therefore, dATP plays a fine-
tuned regulatory role in providing negative feedback from
SAMHD1 to RNR and vice versa [23, 26, 41, 43]. Allosteric
binding of dNTPs is responsible for tetramerization of
SAMHD1 to its functional catalytic state. Tetramer-
disrupting mutations abolish dNTPase activity as well as
the ability of SAMHD1 to restrict HIV-1 infection [23, 42].
Restricting viral infection
SAMHD1 inhibits retroviral replication in non-dividing
cells by depleting the intracellular dNTP pool to a level
that is limiting for viral reverse transcription [9, 38, 39].
In terminally differentiated macrophages and dendritic
cells, or resting CD4+ T-cells with arrested cell cycle
(G0/G1), dNTP levels are significantly decreased by
SAMHD1, and therefore HIV-1 infection is restricted
[9, 38, 39]. Vpx, a protein encoded by HIV-2 or cer-
tain simian immunodeficiency viruses, causes protea-
somal degradation of SAMHD1, which is associated
with an increase in dNTP pool, accelerated proviral DNA
synthesis, and enhanced viral infectivity [9, 38, 39]. Low
cellular dNTP serves as a common mechanism of
SAMHD1-mediated retroviral restriction. In addition to
HIV-1, SAMHD1 also restricts many other retroviruses
and DNA viruses (such as herpes simplex virus 1 and
hepatitis B virus) in non-dividing cells [44–46]. How-
ever, it remains unclear how these viral restriction
studies provide any clues that may link with cell cycle
dysregulation in cancer cells, particularly in the con-
text of viral infection.
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Interaction with cell-cycle regulatory proteins
Phosphorylation at threonine (T) 592 by cyclin
dependent kinases (CDK) regulates dNTPase activity
and HIV-1 restriction activity of SAMHD1 [47–49].
CDK1 as well as CDK2 in complex with cyclin A can
bind to and phosphorylate this site [25, 47–49]. CDK2
interaction with SAMHD1 is regulated by CDK6 in T-
cells and macrophages [50]. Type I IFN reduces phos-
phorylation of SAMHD1 at the T592 residue [47], likely
by inducing CDK inhibitors, such as p21, resulting in
HIV-1 restriction and decreased dNTP pool [50, 51]. For
proper maintenance of dNTP levels, SAMHD1 protein
must be reduced in the cell during S-phase to facilitate
DNA replication [40]. In differentiated human macro-
phages, SAMHD1 interacts with cyclin L2, forming an
ubiquitin ligase complex and resulting in its proteasomal
degradation [52]. However, it is unclear whether the deg-
radation process of endogenous SAMHD1 occurs in
other cell types or in dividing cells. Phosphorylation of
SAMHD1 by CDKs may be the signal for its proteaso-
mal degradation in a cell type- or cell cycle-dependent
manner. With an understanding of SAMHD1 dNTPase
function and dNTP regulation in cancer, we discuss the
physiological consequences of alterations in SAMHD1
expression.
SAMHD1 alterations in an autoimmune disease
and cancers
Mutations of SAMHD1 in an autoimmune disease
SAMHD1 is a negative regulator of IFN-induced innate
immune responses [53]. Aicardi-Goutieres syndrome
(AGS) is an hereditary neurodegenerative autoimmune
disorder that is characterized by progressive encephalop-
athy and is accompanied by increased IFN-α production
[54]. AGS is attributed to defective clearance of excessive
intracellular (self ) nucleic acids, which trigger immune re-
sponses resulting in activation of IFN pathway in a man-
ner that mimics viral infection [10, 55]. SAMHD1
homozygous mutations have been identified in 17 % of pa-
tients with AGS, suggesting a pivotal role of SAMHD1 in
preventing activation of innate immune response to self-
nucleic acids [10]. Further, a homozygous deletion (~9
Kb) in the SAMHD1 gene was identified in patients with
atypical AGS, characterized by genomic instability [56].
Mutations in SAMHD1 result in increased dNTP pools in
fibroblasts from AGS patients [25], suggesting that the
dNTPase function of SAMHD1 prevents autoimmunity
by maintaining genome stability. Together, these studies
implicate SAMHD1 in regulation of self-nucleic acid
stimulated-autoimmune responses.
Mutations of SAMHD1 in cancers
One of the most critical mechanisms by which cancer
cells grow uncontrollably is by inhibiting the function of
tumor suppressor genes [57]. This is achieved mainly
through mutation (leading to loss of function) and/or
downregulation of tumor suppressor genes that normally
arrest cell growth [57]. Studies using CLL patient sam-
ples have identified SAMHD1 mutations in 4 out of 160
cases (2.5 %) [13]. Acquired SAMHD1 mutations were
reported at a frequency of 11 % in relapsed or chemo-
therapy refractory CLL patients and 3 % in the pretreat-
ment group [11]. These findings suggest that SAMHD1
mutation can be an important driving factor contribut-
ing to CLL progression, and can potentially be utilized
as a biomarker for CLL prognosis.
SAMHD1 somatic mutations have been identified in
several human cancers, including chronic lymphocytic
leukemia (CLL) [11, 13, 16], myeloma [18], breast can-
cer [17], lung carcinoma [14], colon and rectal cancer
[17, 19, 58], pancreatic cancer [12], and glioblastoma
[15]. All the identified SAMHD1 alterations in cancer
are summarized in Table 1. Of note, several of these
mutations are located in the catalytic region of HD do-
main of SAMHD1 that is responsible for its dNTPase
activity (Table 1) [7, 8]. However, it is important to note
that it is still unknown whether these specific mutations
in the HD domain of SAMHD1 can directly affect its
dNTPase function. Generation and characterization of
SAMHD1 variants harboring these specific mutations
can help define their activity changes. Importantly,
physiological significance and functional contributions
of these SAMHD1 mutations to progression of cancer
also needs to be investigated, especially since the
SAMHD1 knockout in mice does not result in spon-
taneous tumorigenesis [53, 59]. Further functional
analyses of SAMHD1 mutations identified in human
cancer cells would aid in answering these important
questions.
Downregulation of SAMHD1 expression in cancers
SAMHD1 mRNA levels were significantly lower in CLL
patient B-cells with SAMHD1 mutation relative to nor-
mal B-cells [11]. Although this study suggests that these
mutations result in reduction of SAMHD1 mRNA levels,
the exact mechanism involved in this process is unknown.
It is important to determine whether these mutations lead
to reduced transcription of SAMHD1 or if they cause a
post-transcriptional change such as nonsense-mediated
decay of SAMHD1 mRNA. SAMHD1 expression is also
significantly lower in other cancers, including cutaneous
T-cell lymphoma (CTCL) [20], lung carcinoma [21], breast
carcinomas and various tumor cell lines [11].
CTCL is a subset of non-Hodgkin’s lymphomas that is
characterized by infiltration and proliferation of malig-
nant CD4+ T-lymphocytes into the skin [60]. Decreased
mRNA and protein levels of SAMHD1 were identified in
peripheral blood mononuclear cells (PBMCs) of CTCL
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Table 1 Summary of the identified SAMHD1 alterations in various human cancers
Cancers Identified SAMHD1 alterations References
Gene mutations Epigenetic alterations Consequences
Frequencies Amino acid changes
(domain locations)a, b
Breast cancer 0.4 %c (4/981 cases) N.A. N.A. Reduced SAMHD1 protein [11, 17]
Chronic lymphocytic leukemia 2.5 %a [13] (4/160 cases) N.A. N.A. Reduced SAMHD1 mRNA
and protein
[11, 13, 16]






N.A. N.A. [17, 19, 58]
Cutaneous T-cell lymphoma N.A. N.A. Promoter DNA methylation Reduced SAMHD1 mRNA
and protein
[20]
Glioblastoma 0.3 %c (1/290 cases) N.A. N.A. N.A. [15]
Lung cancer 1.7 %c (4/228 cases) A441T (HD domain)d Promoter DNA methylation Reduced SAMHD1 mRNA
and protein
[14, 21]
Myeloma 1 %c (2/205 cases) Y521D (HD domain)d N.A. N.A. [18]
Pancreatic cancer 1.1 %c (1/91 cases) N.A. N.A. N.A. [12]
N.A. Information not available
aThe mutation details are based on cited literature
bIt is unclear whether all of these mutations in the HD domain of SAMHD1 can directly affect its dNTPase function
cThe mutation rates are based on TCGA data analysis via cBioportal (http://www.cbioportal.org/public-portal/) [67]











patients relative to healthy donors [20]. However, it is un-
known whether decreased SAMHD1 expression has an ef-
fect on CTCL lymphomagenesis, if restored SAMHD1
expression can rescue CTCL phenotype, or whether
SAMHD1 mRNA/protein expression correlates with pa-
tient prognosis. Lung carcinoma patients have reduced
SAMHD1 mRNA and protein [21], but a direct correl-
ation to disease progression or outcome has not been
established. Overexpression of SAMHD1 in a lung cancer
cell line results in decreased proliferation in vitro, with a
concomitant increase in intracellular dNTP levels [21].
Similarly, overexpression of SAMHD1, but not the
dNTPase-defective mutant, can significantly reduce HeLa
cell proliferation [11].
Epigenetic regulation of SAMHD1 in cancers
Epigenetic mechanisms play a major role in cancer de-
velopment and progression by modulating gene expres-
sion [61]. DNA methylation and chromatin remodeling
via histone acetylation or deacetylation are the most im-
portant epigenetic mechanisms through which cancer
cells achieve increased expression of oncogenes or de-
creased expression of tumor suppressor genes [61]. Thus,
many therapeutic strategies target epigenetic mechanisms
in cancer [62].
Studies in lung cancer and CTCL patients have re-
vealed the role of epigenetic mechanisms in downregula-
tion of SAMHD1 expression. The SAMHD1 promoter in
PBMCs of CTCL patients is highly methylated, while it
is unmethylated in PBMCs from healthy donors [20].
This was also observed in human lymphoma/leukemia
CD4+ T-cell lines relative to primary CD4+ T-cells that
have high endogenous SAMHD1 expression [63]. Im-
portantly, treatment with DNA methyltransferase inhibi-
tors in CD4+ T-cell lines rescues SAMHD1 mRNA and
protein expression, validating that DNA methylation has
a direct inhibitory effect on SAMHD1 transcription [63].
Similar effects of SAMHD1 promoter methylation on its
expression were identified in lung cancer tissues [21]. Inter-
estingly, inhibition of histone deacetylation leads to induc-
tion of SAMHD1 mRNA and protein levels in CD4+ T-
cells, suggesting that histone deacetylation also contributes
to repression of SAMHD1 expression [63]. Despite implica-
tions for epigenetic downregulation of SAMHD1 in cancer,
the exact mechanisms are not known. Better understanding
of these pathways may aid in development of therapeutic
strategies targeting epigenetic modifications.
Gene expression is also regulated by microRNAs and
transcription factors. Although, transcription factors that
can regulate SAMHD1 expression are yet to be identi-
fied, one study has indicated that microRNA-181 binds
directly to the 3’ untranslated region of SAMHD1
mRNA and downregulates its expression [64]. Overex-
pression of microRNA-181 in monocytic THP-1 cells
reduced endogenous SAMHD1 mRNA and protein
levels, while microRNA-181 downregulation in T-cell
leukemic-derived Jurkat cells lead to an increase in
SAMHD1 mRNA and protein [64]. It is unclear whether
microRNA-181 downregulates SAMHD1 expression in
cancer patients. Together these findings support the hy-
pothesis that SAMHD1, through its dNTPase function,
could potentially act as a tumor suppressor (Fig. 2).
SAMHD1 may act as a tumor suppressor by
maintaining genome stability
Cancer cells frequently exhibit genomic instability and
are characterized by increased mutation rate, increased
incidence of chromosomal rearrangement, and frequent
retroelement insertions. Many studies demonstrate that
dNTP homeostasis is necessary for maintenance of ac-
curate DNA replication and efficient DNA damage re-
pair [22]. By regulating dNTP homeostasis, SAMHD1
expression has implications in cancer.
SAMHD1 is expressed ubiquitously in undifferentiated
and differentiated cell types to regulate DNA damage
signaling and facilitate proper activation of the innate
immune response [25]. Constitutive DNA damage sig-
naling, as noted in pre-neoplastic cells with genomic in-
stability, is associated with cell cycle delay, senescence,
and upregulation of IFN-stimulated genes. AGS patient
cells have increased sensitivity to genotoxic stimuli, and
respond to DNA damage with increased rates of muta-
genesis [10]. However, it remains unclear whether AGS
patients with SAMHD1 mutations have a higher predis-
position to cancer development. Notably, an AGS pa-
tient harboring a germ line mutation in SAMHD1
developed CLL [11]. Loss of SAMHD1 enhances resist-
ance to chemotherapy-induced DNA damage [11]. Fol-
lowing treatment with DNA-damaging agents, SAMHD1
protein is recruited to sites of double-stranded DNA
breaks and results in increased cell death, a protective
mechanism in cells [11]. In addition to a causal link be-
tween DNA damage signaling and innate immune acti-
vation, SAMHD1 also prevents aberrant synthesis of
DNA species and accumulation of endogenous retroele-
ments that can activate DNA sensors and trigger type I
IFN immune responses [10, 25, 53].
Approximately 17 % of the human genome is com-
posed of retrotransposons that may cause genomic inser-
tions, termed long interspersed elements (LINE) [65].
SAMHD1-mediated LINE1 inhibition is through block-
ing of the reverse transcriptase activity of the element.
Moreover, AGS-associated SAMHD1 mutants are de-
fective in inhibiting LINE1 and silencing SAMHD1 in
cells results in an increase in retrotransposition activity
[65]. Thus, SAMHD1 may play a key role in reducing
random insertions by retroelements that contribute to
genomic instability and lead to cancer development.
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A homozygous large deletion in SAMHD1 was detected
in patients with atypical AGS featuring multiple mitochon-
drial DNA deletions [56], highlighting the importance of
balanced cytoplasmic dNTP pool affecting mitochondrial
pools [40, 56]. Concentrations of dNTPs are highly corre-
lated between cytoplasm and mitochondria in non-
transformed cells [27]. The dNTP levels in both cytoplasm
and mitochondria are critical to fidelity of DNA replication,
mutagenesis, and genome integrity [27, 66]. Thus, loss of
SAMHD1 activity has functional consequences for dysregu-
lated DNA replication, damage repair, and genomic integ-
rity, thereby contributing to tumorigenesis.
Conclusions and perspectives
Mutagenesis and disruption of genomic stability are two
important factors leading to cancer development, which
can be prevented by maintenance of optimal intracellu-
lar dNTP pools. Balanced dNTP levels are required for
DNA damage repair that is necessary to prevent cancer
initiation [22]. Excess intracellular dNTP pool is com-
mon in cancer cells, not only conferring proliferative
ability to the cell, but also posing a challenge for suc-
cessful therapy targeting dNTP metabolism. Nucleoside
analogs have been a mainstay of cancer treatment for
decades [4], however persistently high levels of dNTP in
the cell can out-compete the drug and result in cancer
resistance. Mutations in SAMHD1 have been suggested
to contribute to therapeutic resistance due to a loss of
dNTP hydrolysis [11]. Combination therapies that target
both the synthetic and hydrolytic pathways of nucleo-
tides would likely result in better outcomes. Addition-
ally, restoration of SAMHD1 by targeting the epigenetic
mechanisms using histone deacetylase inhibitors may
sensitize cancer cells to DNA damage-inducing therap-
ies, such as treatment with poly (ADP ribose)-polymer-
ase inhibitors. Therefore, it will be important to invest
further efforts in understanding the complexities of nu-
cleotide metabolism as it relates to regulation of cell
cycle, mutagenesis, and cancer development.
SAMHD1 is a key regulator of dNTP homeostasis via
its dNTPase function [7, 8] and this activity is important
to prevent innate and autoimmune responses [7]. Simi-
larly, dNTPase activity of SAMHD1 could play an anti-
proliferative role in cancer pathophysiology (Fig. 2). Sev-
eral studies in different cancers demonstrated SAMHD1
mutation or downregulation, implicating it as a potential
tumor suppressor. Restoring SAMHD1 expression in can-
cer cell lines leads to decreased cell proliferation support-
ing the hypothesis that SAMHD1 has anti-proliferative
effects in transformed cells [11, 21]. Additionally, SAMHD1
Fig. 2 SAMHD1 may function as a potential tumor suppressor via regulation of dNTPs. SAMHD1 is a novel mammalian dNTP triphosphohydrolase
enzyme that helps in maintenance of intracellular dNTP homeostasis. SAMHD1 has been identified to be downregulated in cutaneous T-cell
lymphoma and lung cancer patient samples via increased promoter DNA methylation. Downregulated SAMHD1 expression may increase the
dNTP pool in these cancers resulting in enhanced DNA replication and thus tumor cell growth and proliferation. On the other hand, overexpression
of SAMHD1 protein upon treatment with DNA damage-inducing agents may result in depleted dNTP pools leading to defective DNA damage repair
mechanisms and thus cell cycle arrest and apoptosis
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may assist in DNA damage response and contribute to cell
cycle regulation (Fig. 2).
Despite rapid progress of structural and functional stud-
ies of SAMHD1, its exact role and mechanisms by which
it regulates cancer cell growth and proliferation remain to
be understood further. In vivo studies of loss of function
and expression of SAMHD1 in cancer are lacking. Al-
though mouse models with SAMHD1 knockout have been
established [53, 59], these mice do not develop spontan-
eous cancers at the age of 70–96 weeks [53, 59], indicating
that SAMHD1 reduction alone is not sufficient to develop
cancer in mice. As with most tumor suppressor genes, it
is likely that additional hits are required. Loss or impaired
SAMHD1 function could confer partial but significant se-
lective advantage to proliferating cancer cells due to an in-
crease or imbalance in intracellular dNTPs (Fig. 2).
Understanding the mechanisms that downregulate
SAMHD1 in cancers is of utmost importance as it could
support developing novel strategies to restore SAMHD1
expression in cancer cells and thus reduce tumorigen-
icity. Epigenetic mechanisms regulate SAMHD1 expres-
sion in CTCL and lung cancers [20, 21]. Identifying the
detailed mechanisms and molecules that are involved
would lead to approaches that restore SAMHD1 to
physiologically normal levels. This may enhance the effi-
cacy of the current DNA damage-inducing strategies in
cancer treatment that target dNTP regulation. In con-
clusion, illumination of the significance of SAMHD1 in
cancer development would open up new avenues of dis-
covery in studying dNTP regulation and cancer biology.
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